NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
Rhea-AI Summary
NewAmsterdam Pharma (Nasdaq: NAMS) will present three digital posters at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28-30, 2026.
The presentations cover obicetrapib kidney outcomes from BROADWAY, a pooled Phase III safety analysis, and LDL particle–CVD risk relationships, with presenters from company leadership and collaborators.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
NAMS warrants rose 5.41% while peers showed mixed moves (e.g., DRMAW +33.72%, KTTAW -8.26%, ASBPW +14.21%). With no peers in the momentum scanner and no same-day peer news, the move appears stock-specific rather than a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 06 | Inducement equity grants | Neutral | -0.8% | Inducement option and RSU grants to new hires under 2024 plan. |
| Feb 18 | Full-year 2025 earnings | Positive | +12.0% | Cash of $728.9M, multiple MAAs accepted, ongoing Phase 3 trials. |
| Feb 06 | Inducement option grants | Neutral | +10.8% | Option grants for 217,000 shares to new hires at $31.57 exercise. |
| Feb 04 | Conference participation | Positive | +7.0% | CFO and EVP presenting at Guggenheim Emerging Outlook Biotech Summit. |
| Jan 09 | Strategic priorities update | Positive | -15.4% | 2025 progress and 2026 priorities for obicetrapib and EMA decision. |
Recent news has often coincided with positive price moves, though a major strategic update in early January saw a sharp negative reaction, indicating occasional divergence between perceived good news and price.
Over the past few months, NewAmsterdam has highlighted regulatory and clinical progress around obicetrapib, including 2025 achievements and 2026 priorities on Jan 9, followed by a detailed full-year 2025 update on Feb 18 that noted $728.9M cash and ongoing Phase 3 programs. Corporate visibility events (a Guggenheim summit appearance and multiple inducement grants) have also featured prominently. Today’s ACC presentation plans continue this pattern of emphasizing obicetrapib’s profile and late-stage data to the cardiovascular community.
Market Pulse Summary
This announcement outlines three ACC.26 presentations showcasing obicetrapib’s effects on kidney function, integrated Phase III safety, and cardiovascular risk metrics. It fits a broader pattern of NewAmsterdam using scientific and medical forums to highlight its late-stage program following prior 2025–2026 updates. Investors tracking the story may focus on how these data complement earlier Phase 3 trials and regulatory filings, and how they position obicetrapib within non-statin lipid-lowering options and cardiovascular risk reduction strategies.
Key Terms
cetp inhibition medical
ldl-c medical
hypercholesterolemia medical
phase iii medical
AI-generated analysis. Not financial advice.
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the at the American College of Cardiology Annual Scientific Session (ACC.26), taking place on March 28-30 in New Orleans, Louisiana.
Presentation details are as follows:
Presentation Title: CETP Inhibition with Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results from the BROADWAY Trial
Session Title: 1069: Next-Generation Lipid Treatment Options
Digital Poster Presentation Date and Time: Saturday, March 28, 2026, 3:30 - 3:37 PM CDT
Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma
Location: Moderated Poster Theater 06, Posters, Hall E
Presentation Title: Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis
Session Title: 1084: Evolving Non-Statin Therapies
Digital Poster Presentation Date and Time: Sunday, March 29, 2026, 10:18 - 10:25 AM CDT
Presenter: Adam Nelson, Ph.D.
Location: Moderated Poster Theater 05, Posters, Hall E
Presentation Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles
Session Title: 1180: Linking Lipid Metrics to CVD Risks
Digital Poster Presentation Date and Time: Monday, March 30, 2026, 11:00 - 11:07 AM CDT
Presenter: Floriaan Schmidt, Ph.D.
Location: Moderated Poster Theater 05, Posters, Hall E
About Obicetrapib
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
